Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Composite Lymphoma 1Breast Neoplasms 1

Interventions

Rituximab 28acalabrutinib 15ibrutinib 14Cyclophosphamide 13venetoclax 10Lenalidomide 10CT-P10 10zanubrutinib 9Magnetic Resonance Spectroscopy 8obinutuzumab 7fludarabine 7Specimen Handling 7Cytarabine 7Bendamustine Hydrochloride 7pirtobrutinib 6Peripheral Blood Stem Cell Transplantation 6Biopsy 6glofitamab 5fludarabine phosphate 5Whole-Body Irradiation 5Cyclosporine 5brexucabtagene autoleucel 4Mycophenolic Acid 4Vincristine 3Stem Cell Transplantation 3Sirolimus 3Methotrexate 3Etoposide 3Doxorubicin 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × ALX148 × 90 days × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡